Psoriasis: KOL Insight

  • ID: 3340135
  • Report
  • Region: Global
  • FirstWord Publishing
1 of 3

FEATURED COMPANIES

  • Amgen
  • AstraZeneca
  • Eli Lilly
  • Johnson & Johnson
  • MORE
There is no shortage of effective treatments for psoriasis, and the introduction of novel anti-IL17 and anti-IL23 antibody-based therapies will further expand the treatment options. How will the market develop in the future as the new classes of drugs find their place in the treatment paradigm and which companies and products will be impacted?

Psoriasis: KOL Insight provides a business critical examination through the expert insights of 12 leading front-line US and European Key Opinion Leaders. Learn what leading clinicians think about current therapies, pipeline candidates, biosimilars and the issues that influence their prescribing decisions.

What do KOLs see as the competing strengths and weaknesses of current and pipeline therapies? What clinical advantages do the new products bring and what challenges do they face? What lessons are there for biosimilar players seeking to grow or enter this market sector? How is cost and funding influencing prescribers? Gain key insights in Psoriasis: KOL Insight.

Key Benefits

- Know the detailed opinions of leading front-line clinicians on current and pipeline psoriasis therapies and what they see as the critical advantages/disadvantages affecting their prescribing decisions
- Appreciate the important factors around dosage, drug sequencing, administration, patient information and funding and identify key areas for strategic and tactical action
- Understand what KOL’s see as the critical unmet needs in the sector
- Drive change through better clinician and patient engagement
- Review KOL attitudes to important clinical trials such as CLEAR, FIXTURE, ERASURE, ESTEEM and AMAGINE

Answers to Critical Questions

- How might long clinical experience and safety data be leveraged by AbbVie to defend Humira revenues in the face of growing competition?
- What data would KOL’s like from Novartis to strengthen their view of Cosentyx?
- How might J&J overcome payer barriers and establish Stelara as a first line treatment choice?
- What concerns do KOLs have about the increasing number of biosimilars entering the market and to what extent may they affect their prescribing decisions?
- Amgen/AstraZeneca’s brodalumab, Eli Lilly’s ixekizumab and J&J guselkumab are all progressing through trials: what do see KOL’s see as their competing benefits?
- Pricing is a contentious issue often limiting patient access – what can be done?
- What opportunities are there for diagnostic technologies to better identify patient receptiveness to treatment?
- What development opportunities are there for the poorly serviced mild to moderate patient group?

Report Features

- Knowledgeable real world opinions of leading US and European KOLs on the competing advantages, disadvantages and prospects for current and pipeline psoriasis therapies
- Treatment options mapped to plaque psoriasis patient sub groups and why particular therapy is chosen
- Administration, dosage and safety characteristics KOLs think are the most important in terms of prescribing decisions
- KOL views on potential impact of biosimilars on reference products
- A review of early stage programmes for emerging approaches such as Toll-like receptors, Anti-CD162, Anti-CD4/CD25 and A3 adenosine receptor agonists
READ MORE
Note: Product cover images may vary from those shown
2 of 3

Loading
LOADING...

3 of 3
- Amgen
- AstraZeneca
- Eli Lilly
- Johnson & Johnson
Note: Product cover images may vary from those shown
4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll